In Simple Terms
A study found that the body’s blood proteins change as women go through menopause. Some of those changes were linked to weaker results on later thinking tests and a slightly higher chance of an Alzheimer’s dementia diagnosis. The findings do not show that menopause causes the disease or that any particular woman will develop it.
What Do Blood Proteins Measure?
Menopause does not affect the ovaries alone. The hormonal shifts of this life stage happen alongside broader changes in the body, and some may involve processes related to brain health. A multi-institutional study published in Nature Medicine on November 2, 2026, found that a group of blood proteins changed during the menopausal transition. Higher levels of some of these proteins were later associated with cognitive measures and a modestly higher likelihood of Alzheimer’s dementia.
Proteins perform many jobs throughout the body. Measuring them in blood can provide clues about biological activity in tissues. But finding a protein associated with the brain does not mean a blood sample directly reveals what is happening inside the brain, nor does it mean that protein causes disease. Taken together, patterns across many proteins may help researchers map changes that accompany a particular stage of life or biological state.
The researchers asked a question that goes beyond the familiar symptoms of menopause: Does declining ovarian function coincide with measurable changes in blood proteins, and do those changes overlap with processes relevant to brain health and aging? The team was led by researchers from the University of California, Santa Barbara, and the University of California, San Francisco, with contributions from the Sunnybrook Research Institute in Toronto and other institutions. The study’s senior researchers included Emily Jacobs of Santa Barbara and Kaitlin Casaletto of the Memory and Aging Center in San Francisco.
Starting With 80 Women at Different Stages
For the first part of the study, the researchers analyzed serum samples from 80 women aged 43 to 58. Using the established STRAW+10 criteria, they carefully classified participants as premenopausal, in the menopausal transition, or postmenopausal. The team used an advanced protein-analysis method called NULISAseq to measure a broad range of proteins and compare patterns across the groups.
The analysis suggested that changes linked to the transition involved more than one biological pathway. They included processes related to inflammation, the function of synapses, metabolism, and biology associated with Alzheimer’s disease. The researchers identified a network of 16 proteins whose levels changed during the transition. These proteins were linked to functions including regulating inflammatory responses, maintaining communication between nerve cells, and supporting the integrity of neural structures.
Separating the effects of hormonal stage from those of age is especially important. After accounting for chronological age, the protein changes appeared more closely associated with hormone measures and a woman’s stage of menopause than with the number of years she had lived. That does not mean age is irrelevant to brain health. It does suggest, however, that age alone may not explain the changes seen during this stage, and that hormonal transition may coincide with measurable shifts in biology.
Testing the Findings in a Larger Group
The team did not rely on the initial results alone: 80 participants is a limited sample and cannot, by itself, support broad conclusions. The researchers therefore tested the pattern in data from 2,814 women in the UK Biobank, comparing women of similar ages who were at different stages of menopause. In this part of the study, they measured proteins in plasma using Olink, a different technology from the one used in the first group.
This comparison supported the presence of protein changes associated with the menopausal transition and broadened the picture. It showed higher levels of markers of inflammation and catabolic processes—the breakdown of cellular or tissue components. The researchers also found patterns consistent with faster aging in some cells and organs, including the brain. Seeing similar signals in an independent sample, measured with a different tool, increases confidence that the findings were not simply a chance result in the small initial group.
Still, describing these patterns as associated with faster aging does not mean the study proved that every woman’s organs age at the same rate during menopause, or that protein changes directly cause damage. Rather, several biological measures shifted in a direction consistent with changes in aging-related processes. The relationship merits further study to understand what drives it and what it may mean for an individual’s health.
Cognitive Follow-Up Lasted Up to 16 Years
To find out whether the protein signature was more than a laboratory change with no clear connection to later outcomes, the team examined data from four independent groups of older women. Together, the groups included 11,925 participants, and their average ages ranged from 60.7 to 72.1 years. The researchers compared scores on the menopause-related protein signature with results from cognitive tests and data on dementia.
A similar pattern emerged across the groups: on average, women with higher scores on the protein signature performed less well on measures of cognition. In the largest follow-up group, higher levels of the signature were associated with a modestly greater likelihood of an Alzheimer’s dementia diagnosis over a period of up to 16 years. Finding the association in four independent groups makes it worth pursuing, but it does not make the result a certain prediction about any individual woman’s future.
The distinction between association and cause is essential. The study observed patterns that occurred together: the menopausal stage was associated with some protein changes, and those changes were in turn associated with later cognitive measures and dementia risk in other groups. But the findings do not prove that hormonal changes alone produced the protein shifts, or that the proteins themselves led to disease. Dementia has many contributing factors. Most women do not develop Alzheimer’s, and these results cannot identify who will.
Why Researchers Are Looking at Midlife
Midlife matters because measurable changes may appear many years before noticeable memory problems. This stage could offer a chance to learn how risk factors and resilience take shape. Resilience refers to conditions that may help the brain maintain its function. The study suggests that the menopausal transition can be a useful point at which to investigate brain health—not because it inevitably sets a woman on a path to disease, but because it comes with biological changes that researchers can track.
This research also sits within a broader context: women make up about two-thirds of people with Alzheimer’s, and a woman spends close to one-third of her life after menopause. These figures do not, on their own, explain differences between the sexes or prove that menopause is responsible for them. They do underscore the importance of studying women’s brain health across the lifespan, especially in midlife, when hormonal changes begin.
The researchers say the protein signature could eventually help identify biomarkers or treatment targets worth testing. One possibility under discussion is a blood test that might someday help estimate risk, much as some laboratory measures are used to assess heart-disease risk. But this remains a future research idea, not a clinical test ready for use or an approved way to diagnose Alzheimer’s. Before such a test could be considered, researchers would need to determine which proteins are most useful, how accurately they can be measured, whether the findings can be replicated, and whether they apply to diverse groups of people.
What the Study Does Not Tell Us
The findings do not show that menopause causes Alzheimer’s, or that a rise in any single protein means dementia will develop later. They also do not show that changing hormone levels or taking a particular treatment will prevent the disease: the study did not test preventive treatment or compare the effectiveness of medical interventions. Nor does it give women a way to calculate their personal risk. The signal appeared at the group level, and the meaning of any individual protein change for a particular person remains uncertain.
Important questions remain. How do these measures change within the same woman over time? What roles do hormonal fluctuations and related symptoms play, and how much do other factors that affect inflammation and aging contribute? Can a blood-protein signature distinguish between different paths of brain health, or does it reflect general changes throughout the body? Answering these questions will require longer follow-up, repeated measurements, and more precise links between proteins and nervous-system function.
To pursue these questions, teams in Santa Barbara and San Francisco are working to launch a national, long-term project following women from midlife into later stages of life. The project aims to track hormonal and protein changes, symptoms, and neurological changes over time. This kind of follow-up could clarify the sequence of events: what appears first, what changes in parallel, and which factors are later associated with resilience or higher risk.
The Bottom Line
The study links the menopausal transition with changes in blood proteins related to inflammation, nerve-cell function, and aging processes. It began with 80 women aged 43 to 58, was supported by findings in 2,814 women, and then compared the protein signature with outcomes in four groups totaling 11,925 women, whose average ages ranged from 60.7 to 72.1 years. Higher scores were associated with weaker cognitive performance and a modestly greater risk of Alzheimer’s dementia during follow-up lasting up to 16 years. These are associations, not proof of cause, and they cannot predict with certainty whether any woman will develop the disease. Their main value is in opening a new path for studying brain health in midlife; much more research is needed before these measures could guide screening or treatment.